Trial report in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04953715 (Microbiome and Immunosuppression), which is not on this map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Microbiome and Immunosuppression: The Mission Study
TypeobservationalSponsorThe University of Texas Medical Branch, GalvestonRan2020 to 2033Enrolled140ConditionsKidney Transplant Rejection, Kidney TransplantArmscollection of body microbiome
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Moataz E MohamedDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN, 55455, USA.ORCID 0000-0002-7266-9980
Abdelrahman SaqrDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN, 55455, USA.ORCID 0000-0002-8280-1375
Guillaume OnyeaghalaDivision of Nephrology, University of Texas Medical Branch, Galveston, TX, 77555, USA.ORCID 0000-0001-8090-5640
Rory P RemmelDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0002-1532-1726
Christopher StaleyDepartment of Surgery, School of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0002-2309-0083
Casey R DorrDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN, 55455, USA.ORCID 0000-0002-6108-280X
Levi TeigenDepartment of Food Science and Nutrition, University of Minnesota, St. Paul, MN, 55108, USA.ORCID 0000-0002-6409-0485
Weihua GuanDivision of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0002-0956-9821
Duy VoDivision of Nephrology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Rasha El-RifaiDivision of Nephrology and Hypertension, School of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0002-4809-2288
William S OettingDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN, 55455, USA.ORCID 0000-0002-1076-0711
Arthur J MatasDepartment of Surgery, School of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0001-9957-639X
Ajay K IsraniDivision of Nephrology, University of Texas Medical Branch, Galveston, TX, 77555, USA.ORCID 0000-0002-7607-0430
Pamala A JacobsonDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN, 55455, USA. jacob117@umn.edu.ORCID 0000-0002-4145-7045
Funding
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UM1TR004405 · NCATS · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar, Damien A Fair · 2023 to 2026
$30.8M
Gut Microbiota and Effect on Immune Suppressants in TransplantationR01AI140303 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GUAN, WEIHUA, ISRANI, AJAY K · 2019 to 2024
$3.6M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases 5R01AI140303NCATS NIH HHS UM1 TR004405NIAID NIH HHS R01 AI140303
6 · The paper itself
Abstract
backgroundMycophenolic acid (MPA) has complex pharmacokinetics in part due to enterohepatic recirculation (EHR). A deeper understanding of MPA pharmacokinetics and specifically how EHR and patterns of EHR affect exposure will improve immunosuppression outcomes. This study provides a contemporary and comprehensive assessment of MPA and metabolites in the blood and urine with a focus on EHR characteristics.
methodsKidney transplant recipients (n = 84) receiving mycophenolate mofetil (MMF) and tacrolimus underwent an intensive MPA pharmacokinetic assessment. Pharmacokinetics of MPA and its metabolites, EHR%, and number of secondary peaks were determined. The associations between EHR, the number of secondary peaks, and achievement of MPA therapeutic range were studied. MMF dose proportionality with MPA exposure was evaluated.
resultsMPA exhibited high pharmacokinetic variability, with 5.5-fold differences in AUC
conclusionsThere was no association between the EHR% and MPA AUC TRIAL REGISTRY: Clinical Trial Notation: clinicaltrials.gov, NCT04953715.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients. · full record | OpenQuestion